Computational study of the phosphoryl transfer catalyzed by a cyclin-dependent kinase

被引:41
|
作者
De Vivo, Marco
Cavalli, Andrea
Carloni, Paolo
Recanatini, Maurizio
机构
[1] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy
[2] INFM Democritos, I-34014 Trieste, Italy
[3] ISAS, SISSA, Int Sch Adv Studies, I-34014 Trieste, Italy
关键词
density functional calculations; enzymatic catalysis; molecular dynamics; reaction mechanisms; transition state analogues;
D O I
10.1002/chem.200700044
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A cyclin-dependent kinase, Cdk2, catalyzes the transfer of the gamma-phosphate from ATP to a threonine or serine residue of its polypeptide substrates. Here, we investigate aspects of the reaction mechanism of Cdk2 by gas-phase density functional calculations, classical molecular dynamics, and Car-Parrinello QM/MM simulations. We focus on the role of the conserved Asp127 and on the nature of the phosphoryl transfer reaction mechanism catalyzed by Cdk2. Our findings suggest that Asp127 is active in its deprotonated form by assisting the formation of the near-attack orientation of the substrate serine or threonine. Therefore, the residue does not act as a general base during the catalysis. The mechanism for the phosphoryl transfer is a single S(N)2-like concerted step, which shows a phosphorane-like transition state geometry. Although the resulting reaction mechanism is in agreement with a previous density functional study of the same catalytic reaction mechanism (Cavalli et al., Chem. Comm. 2003, 1308-1309), the reaction barrier is considerably lower when QM/MM calculations are performed, as in this study (approximate to 42 kcalmol(-1) QM vs approximate to 24 kcalmol(-1) QM/MM); this indicates that important roles for the catalysis are played by the protein environment and solvent waters. Because of the high amino acid sequence conservation among the whole family of cyclin-dependent kinases (CDKs), these results could be general for the CDK family.
引用
收藏
页码:8437 / 8444
页数:8
相关论文
共 50 条
  • [31] Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs
    Krystof, Vladimir
    Uldrijan, Stjepan
    CURRENT DRUG TARGETS, 2010, 11 (03) : 291 - 302
  • [32] Cyclin-dependent kinase-5 in neurodegeneration
    Shelton, SB
    Johnson, GVW
    JOURNAL OF NEUROCHEMISTRY, 2004, 88 (06) : 1313 - 1326
  • [33] Cyclin-dependent kinase control of motile ciliogenesis
    Vladar, E. K.
    Stratton, M. B.
    Stearns, T.
    Axelrod, J. D.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [34] Extraneuronal roles of cyclin-dependent kinase 5
    Rosales, Jesusa L.
    Lee, Ki-Young
    BIOESSAYS, 2006, 28 (10) : 1023 - 1034
  • [35] Ras versus cyclin-dependent kinase inhibitors
    Lloyd, AC
    CURRENT OPINION IN GENETICS & DEVELOPMENT, 1998, 8 (01) : 43 - 48
  • [36] Cyclin-Dependent Kinase Modulators and Cancer Therapy
    Gallorini, Marialucia
    Cataldi, Amelia
    di Giacomo, Viviana
    BIODRUGS, 2012, 26 (06) : 377 - 391
  • [37] Selectivity and potency of cyclin-dependent kinase inhibitors
    Sridhar, J
    Akula, N
    Pattabiraman, N
    AAPS JOURNAL, 2006, 8 (01): : E204 - E221
  • [38] Natural analogues inhibiting selective cyclin-dependent kinase protein isoforms: a computational perspective
    Singh, Rahul
    Bhardwaj, Vijay
    Das, Pralay
    Purohit, Rituraj
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2020, 38 (17): : 5126 - 5135
  • [39] Cyclin-dependent Kinase 5 and Neurodegenerative Diseases
    Song, Mingxue
    Qiang, Yalong
    Zhao, Xiulan
    Song, Fuyong
    MOLECULAR NEUROBIOLOGY, 2024, 61 (10) : 7287 - 7302
  • [40] Selectivity and potency of cyclin-dependent kinase inhibitors
    Jayalakshmi Sridhar
    Nagaraju Akula
    Nagarajan Pattabiraman
    The AAPS Journal, 8